Observational studyAmerican journal of hematology2026

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Mónica Alejandra Romero Riquelme et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.